By Wesley Brown ( June 18, 2026, 18:45 GMT | Insight) -- Aurobindo Pharma Limited will be required to divest four drug products in order to complete its $250 million acquisition of Lannett Company, as ordered by the US Federal Trade Commission. The government is requiring the divestiture of four drug products: Mycophenolate mofetil oral suspension, Niacin extended release tablets, Pilocarpine tablets and Rabeprazole sodium delayed release tablets, to Quagen Pharmaceuticals.Aurobindo Pharma Limited will be required to divest four drug products in order to complete its $250 million acquisition of Lannett Company, as ordered by the US Federal Trade Commission....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.